Epizyme Files for an IPO
Epizyme, a six-year-old, Cambridge, Mass.-based biopharmaceutical company that's focused on researching treatments for tumors and blood cancer, has filed an S-1 with the SEC.
18 April 2013•1 min read
Epizyme, a six-year-old, Cambridge, Mass.-based biopharmaceutical company that's focused on researching treatments for tumors and blood cancer, has filed an S-1 with the SEC.
